[Image: masthead]

24-HOUR MH HOTLINE

800-644-9737

Outside NA: 001-209-417-3722
FOR EMERGENCIES ONLY

24-HOUR MH HOTLINE: 800-644-9737
Outside NA: 001-209-417-3722
FOR EMERGENCIES ONLY

Archived References

Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005;135:249-256.

Ananth, J, Parameswaran, S, Gunatilake, S, Burgoyne, K, Sidhom, T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-470.

Gupta S: New Approaches to the treatment of dopamine blocking agent induced movement disorders: Drug-Induced Movement Disorders, Editor Sethi KD, Marcel Dekker, Inc. New York (2004)

Gupta S, Nihalani N: Neuroleptic Malignant Syndrome: A primary care perspective. Primary Care Companion J Clin Psychiatry 2004; 6:191-194

Mann SC, Caroff SN, Keck PE, Lazarus A.  Neuroleptic Malignant Syndrome and Related             Conditions, 2nd Edition.   American Psychiatric Press Inc, Washington DC, 2003.

Caroff, S.N., Rosenberg, H., Mann, S.C., Campbell, E.C., Gliatto, M.F., Sullivan K.A. Neuroleptic malignant syndrome in the perioperative setting.  Amer J Anesthesiology 28: 387-393, 2001.

Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30 (5):314-321.

Caroff SN, Mann SC, Keck PE, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol, 2000; 20: 257-259.

Gupta S, Racaniello AA: Neuroleptic malignant syndrome associated with Amoxapine and Lithium in an older adult. Annals of Clinical Psychiatry, 2000; 12:107-109.

Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30 (5):325-331.

Francis, A., Koch, M., Chandragiri S., Rizvi, S., Petrides, G. Is Lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectrums, 2000.

Fricchione GE, Mann SC, Caroff SN. Catatonia, lethal catatonia, and neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30:347-355.

Keck, PE, Arnold, LM: Serotonin syndrome. Psychiatric Annals, 2000; 30 (5):333-343.

Koch, M., Chandragiri, S., Rizvi, S., Petrides, G, and Francis, A. Catatonic signs in neuroleptic malignant syndrome, Comprehensive Psychiatry, 2000; 41: 73-75.

Mann SC, Caroff SN, Fricchione GE, Campbell EC: Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30 (5):363-374 .

Adityanjee, Mathews T, Aderibigbe YA: Proposed research diagnostic criteria for neuroleptic malignant syndrome. International Journal of Neuropsycholpharmacology, 1999; 2:129-144.

Adityanjee, Aderibigbe, YA, Mathews, T: Epidemiology of Neuroleptic malignant syndrome. Clinical Neuropharmacology, 1999; 2:151-158.

Gurrera RJ: Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry, 1999; 156: 169-180.

Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol, 1998; 18: 349-351.

Gurrera RJ, Chang SS: Thermoregulatory dysfunction in neuroleptic malignant syndrome. Biol Psychiatry, 1996; 39:207-212.

Gurrera RJ: Diaphoresis and dehydration during neuroleptic malignant syndrome: preliminary findings. Psychiatry Res, 1996; 64:137-145.

Francis, A., Divadeenam, K., Petrides, G. Advances in treatment of catatonia with lorazepam and ECT, Convulsive Therapy, 1996; 12:259-261.

Keck PE, Caroff SN, McElvroy SL. Neuroleptic malignant syndrome and malignant hyperthermia - end of a controversy? J Neuropsychiatry Clin Neurosci, 1995; 7 135-144.

Velamoor VR, Swamy GN, Parmar RS, et al: Management of suspected neuroleptic malignant syndrome. Can J Psychiatry, 1995; 40: 545-550.
 
Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin No Amer, 1993; 185-202.

Davis JM, Janicak PG, Sakkas P, et al: Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convulsive Therapy, 1991; 7:111-120.

Mann SN, Caroff SN, Bleier HR, et al. Electroconvulsive therapy in the treatment of lethal catatonia: case report and review. Convulsive Therapy, 1990; 6: 239-247.

Gelenberg AJ, Bellinghausen B, Wojcik JD, et al: Patients with neuroleptic malignant syndrome histories: What happens when they are rehospitalized? J Clin Psychiatry, 1989; 50: 178-180.

Keck PE, Pope HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry, 1989; 46: 914-918.

Rosebush PI, Stewart TD, Gelenberg AJ: Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry, 1989; 50: 295-298.

Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 717-775.

Mann SC, Caroff SN, Bleier HR, et al. Lethal catatonia. Am J Psychiatry, 1986; 1374-1381.

Caroff, S.N.:  The neuroleptic malignant syndrome.  J Clin Psychiatry, 41:79-83, 1980.

[Image: MHAUS logo]
The mission of MHAUS is to promote optimum care and
scientific understanding of MH and related disorders.
© 2024 Malignant Hyperthermia Association of the United States. All rights reserved. The claims and opinions expressed in sponsor advertising found on this website are those of the advertiser and not necessarily the views or opinions of MHAUS, its staff or its advertisers. As a matter of policy, MHAUS representatives and clinical experts will not give advice to patients concerning their individual clinical circumstances. The MHAUS corporation does not provide funds or other support directly or indirectly for administrative overhead to institutions.